Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Bond

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Blood|July 27, 2021
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinibAdam S Kittai, Cecelia Miller, Daniel Goldstein, et al.
British Journal of Haematology|July 1, 2025
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphomaJohn Sharp, Qiuhong Zhao, Timothy J Voorhees, et al.
British Journal of Haematology|December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapyDaniel J Landsburg, Emily C Ayers, David A Bond, et al.
Blood Advances|June 12, 2023
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphomaDiego Villa, Aixiang Jiang, Carlo Visco, et al.
Pediatric Blood & Cancer|March 22, 2025
Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B-Cell Lymphomas Treated at an Adult Versus Pediatric Cancer CenterAllison M LeHanka, Ann M Kebede, Neda Amirmokhtari, et al.
Blood Advances|October 1, 2020
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndromeAdam S Kittai, David A Bond, Basem William, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Cancers|March 11, 2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's LymphomaWalter Hanel, Polina Shindiapina, David A Bond, et al.
Blood Advances|November 25, 2025
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell LymphomaJia Ruan, David A Bond, Bijal D Shah, et al.
Blood|September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Blood|July 27, 2021
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinibAdam S Kittai, Cecelia Miller, Daniel Goldstein, et al.
British Journal of Haematology|July 1, 2025
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphomaJohn Sharp, Qiuhong Zhao, Timothy J Voorhees, et al.
British Journal of Haematology|December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapyDaniel J Landsburg, Emily C Ayers, David A Bond, et al.
Blood Advances|June 12, 2023
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphomaDiego Villa, Aixiang Jiang, Carlo Visco, et al.
Pediatric Blood & Cancer|March 22, 2025
Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B-Cell Lymphomas Treated at an Adult Versus Pediatric Cancer CenterAllison M LeHanka, Ann M Kebede, Neda Amirmokhtari, et al.
Blood Advances|October 1, 2020
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndromeAdam S Kittai, David A Bond, Basem William, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Cancers|March 11, 2023
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's LymphomaWalter Hanel, Polina Shindiapina, David A Bond, et al.
Blood Advances|November 25, 2025
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell LymphomaJia Ruan, David A Bond, Bijal D Shah, et al.
Blood|September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Pageof 6